Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma.
Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis
Tags: amethopterin, antifolate antimetabolite, autoimmune diseases, cancer, chemotherapy, dihydrofolate reductase (DHFR) inhibitor, immunosuppressant, MTX, Otrexup®, Rasuvo®, rheumatoid arthritis, Rheumatrex®, Trexall®
BASi Method Number SAP.1841
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
